# Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

> **NCT02709005** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 109 (actual)

## Conditions studied

- Bacterial Vaginosis

## Interventions

- **DRUG:** 5% Monolaurin Vaginal Gel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02709005
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-14
- **Primary completion:** 2017-12-11
- **Final completion:** 2017-12-11
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2018-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709005, "Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02709005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*